The largest study to date, conducted across 11 different countries, however, yielded contradictory results, noting a significantly increased risk of endometrial cancer in BRCA1 pathogenic variant carriers and those exposed to tamoxifen [5]. Here, BRCA1 is linked to endometrial cancer.